ReviewInternational journal of molecular sciences2026
Nanoparticle-Based Biomaterials in Cancer Research: From Mechanistic Insights to Therapeutic Innovation.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the most complex diseases to study and treat, with tumour microenvironment heterogeneity and therapeutic resistance continuing to limit clinical progress. Biomaterials-based nanoparticles have emerged as versatile platforms that not only advance understanding of cancer biology but also enable innovative therapeutic strategies. As mechanistic tools, nanoparticles can be used to investigate extracellular matrix interactions, mechanotransduction pathways, drug resistance, and tumour-immune crosstalk, providing insights into how physical and biochemical cues influence disease progression. Therapeutically, engineered nanoparticle systems have been developed for the targeted delivery of chemotherapeutics, nucleic acids, and immunomodulatory agents, incorporating features such as stimuli-responsive release, multifunctionality, and theranostic capabilities. Recent advances in patient-derived tumour models, high-throughput screening platforms, and artificial intelligence-assisted design are further driving the development of precision nanomedicine. Despite ongoing challenges related to biodistribution, safety, manufacturing scalability, and regulatory approval, nanoparticle-based biomaterials offer significant opportunities to bridge fundamental cancer research and clinical translation. This review highlights recent mechanistic and therapeutic advances, discusses key translational barriers, and outlines future directions at the interface of biomaterials, nanotechnology, and oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.